Bicara Therapeutics (BCAX) Assets Average (2024 - 2026)

Bicara Therapeutics' Assets Average history runs 3 years deep, the most recent figure standing at $492.3 million for Q1 2026.

• On a quarterly basis, Assets Average changed 0.35% year-over-year to $492.3 million in Q1 2026; TTM through Mar 2026 was $492.3 million, a 0.35% change from a year earlier, with the FY2025 full-year figure at $470.5 million, up 26.48% from the prior year.
• Assets Average rose to $492.3 million in Q1 2026 per BCAX's latest filing, from $427.8 million in the prior quarter.
• Across five years, Assets Average topped out at $517.1 million in Q4 2024 and bottomed at $427.8 million in Q4 2025.
• The 3-year median for Assets Average is $479.1 million (2025), against an average of $472.7 million.
• Across the five-year window, Assets Average dropped 17.26% in 2025 and decreased 0.35% in 2026, its largest moves.
• Year by year, Assets Average stood at $517.1 million in 2024, then retreated by 17.26% to $427.8 million in 2025, then advanced by 15.07% to $492.3 million in 2026.
• Per Business Quant, the three latest BCAX Assets Average figures stand at $492.3 million (Q1 2026), $427.8 million (Q4 2025), and $439.1 million (Q3 2025).